By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is ...

Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with ...

Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...

U.S. suspends Ixchiq vaccine license due to serious side effects, raising concerns over chikungunya virus spread globally.

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

The decision to suspend the Ixchiq vaccine comes as public health experts warn the mosquito-spread virus could pose a future pandemic threat.

Hey, good morning. Today, we see CBER suspend the license for a chikungunya vaccine, look at a push to recall a safety and ...

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...

US health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

Valneva (VALN) stock in focus as the FDA suspends its chikungunya vaccine Ixchiq due to safety issues, including deaths. Read ...